RxDoctor Payments Data

Anthony Greco, MD

Pulmonary Disease · Des Moines, IANPI 1073909545

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (35.7%), food and beverage and education — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 66.9% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $1,253, more than ten times the $18 reported in 2019.

$2,532in general payments, 2019–2025

Across 28 payments — averaging $90.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Bayer$200
  • Verona Pharma, Inc.$121
  • Grifols USA, LLC$83
  • Daiichi Sankyo Inc.$73
  • Conmed Corporation$63
  • plus $297 from 9 others

What the payments were for

  • Consulting fees$2008%
  • Travel & lodging$90436%
  • Food & beverage$72729%
  • Education$70028%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,532 in reported general payments places this provider in the 60th percentile of 110 pulmonary disease providers in Iowa.

See all pulmonary disease providers in Iowa

Medicare billing

Part B allowed, 2024
$143,502
Medicare patients
505
Services billed
1,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate27$365,848
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr92$45,245
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$43,488
Stiolto RespimatTiotropium Br/Olodaterol Hcl73$38,427
Spiriva RespimatTiotropium Bromide29$20,384
Breo ElliptaFluticasone/Vilanterol33$13,976
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$8,842
Combivent RespimatIpratropium/Albuterol Sulfate12$6,022
Advair HfaFluticasone Propion/Salmeterol14$5,193
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$3,351
Ventolin HfaAlbuterol Sulfate29$1,587
Albuterol Sulfate HfaAlbuterol Sulfate41$1,348
Azithromycin30$491
Fluticasone Propionate38$332
Montelukast Sodium63$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$33$430,681141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 110 pulmonary disease providers in Iowa.

Other pulmonary disease in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →